3B Blackbio DX Ltd

3B Blackbio Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

3B Blackbio DX Ltd

₹ 1,133 -2.10%
03 Jul 9:05 a.m.
kilpest.com BSE: 532067
About

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]

Key Points

Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit

Website BSE
  • Market Cap ₹ 973 Cr.
  • Current Price ₹ 1,133
  • High / Low ₹ 1,262 / 410
  • Stock P/E 30.3
  • Book Value ₹ 260
  • Dividend Yield 0.22 %
  • ROCE 21.0 %
  • ROE 16.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 18.0%
  • Promoter holding has increased by 2.86% over last quarter.

Cons

  • Earnings include an other income of Rs.12.5 Cr.
  • Company has high debtors of 179 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
18.88 32.67 15.22 14.36 18.40 11.69 17.31 14.73 18.11 14.28 19.18 17.67 23.00
10.37 14.46 9.22 7.39 12.48 6.51 8.13 7.42 10.65 7.84 11.39 8.80 13.12
Operating Profit 8.51 18.21 6.00 6.97 5.92 5.18 9.18 7.31 7.46 6.44 7.79 8.87 9.88
OPM % 45.07% 55.74% 39.42% 48.54% 32.17% 44.31% 53.03% 49.63% 41.19% 45.10% 40.62% 50.20% 42.96%
1.19 1.55 1.94 1.54 1.87 1.24 1.96 2.88 1.15 2.96 2.75 2.63 4.19
Interest 0.04 0.03 0.06 0.03 -0.02 0.03 0.07 0.05 0.04 0.02 0.04 0.03 0.04
Depreciation 0.11 0.15 0.18 0.17 0.17 0.17 0.24 0.25 0.21 0.19 0.24 0.32 0.30
Profit before tax 9.55 19.58 7.70 8.31 7.64 6.22 10.83 9.89 8.36 9.19 10.26 11.15 13.73
Tax % 25.55% 23.70% 23.64% 21.06% 36.91% 24.12% 23.27% 22.04% 37.80% 21.55% 26.02% 23.68% 35.98%
7.10 14.94 5.88 6.56 4.82 4.72 8.31 7.72 5.19 7.21 7.58 8.51 8.79
EPS in Rs 8.24 17.53 6.85 7.66 5.53 5.39 11.20 8.96 7.72 9.71 10.46 10.16 10.33
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
20 22 19 17 16 23 23 29 227 81 62 74
19 21 18 16 14 18 16 20 77 44 33 41
Operating Profit 1 1 1 2 3 5 7 9 150 37 29 33
OPM % 6% 6% 7% 9% 16% 23% 31% 32% 66% 46% 47% 44%
0 0 0 0 0 0 1 2 3 7 7 13
Interest 1 1 1 1 1 1 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 1 1 1 1 1 1
Profit before tax 1 0 0 0 1 5 7 10 152 43 35 44
Tax % 34% 14% 23% 23% 19% 24% 25% 23% 25% 26% 27% 28%
0 0 0 0 1 3 5 8 114 32 26 32
EPS in Rs 0.62 0.59 0.36 0.51 1.76 5.35 8.18 10.24 151.66 42.89 34.55 38.13
Dividend Payout % -0% -0% -0% -0% 17% 9% 6% 7% 6% 24% 7% -0%
Compounded Sales Growth
10 Years: 13%
5 Years: 26%
3 Years: -31%
TTM: 20%
Compounded Profit Growth
10 Years: 56%
5 Years: 44%
3 Years: -34%
TTM: 24%
Stock Price CAGR
10 Years: 65%
5 Years: 66%
3 Years: 24%
1 Year: 170%
Return on Equity
10 Years: 33%
5 Years: 35%
3 Years: 18%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 6 6 6 6 6 6 6 7 7 7 7 9
Reserves 3 4 4 4 5 12 16 25 125 146 164 214
6 7 8 8 9 6 6 4 2 3 2 1
7 7 7 6 6 6 8 9 59 37 41 24
Total Liabilities 23 24 25 24 26 30 36 45 194 192 214 248
4 4 4 3 3 4 4 4 5 7 8 7
CWIP -0 -0 -0 -0 0 0 0 0 0 0 0 -0
Investments -0 -0 -0 -0 -0 -0 -0 1 59 93 92 117
19 20 21 21 22 26 32 40 130 93 114 123
Total Assets 23 24 25 24 26 30 36 45 194 192 214 248

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-1 0 0 1 1 2 4 7 98 37 23 27
0 -0 -0 -0 -0 -1 -1 -1 -70 -28 12 -20
-0 0 -0 -1 -0 0 -1 1 -2 -15 -5 -4
Net Cash Flow -1 0 -0 0 -0 1 2 7 26 -6 30 3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 220 213 262 283 321 259 290 252 56 136 200 179
Inventory Days 149 120 145 143 175 141
Days Payable 220 189 218 203 186 66
Cash Conversion Cycle 149 144 188 223 310 259 290 252 56 136 200 253
Working Capital Days 214 218 274 312 377 308 351 302 67 169 248 216
ROCE % 8% 7% 7% 7% 13% 24% 28% 31% 162% 27% 19%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
38.35% 38.35% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 41.29%
1.47% 0.54% 1.23% 1.64% 1.64% 1.64% 2.11% 2.54% 3.06% 3.16% 3.38% 2.97%
0.09% 0.08% 0.08% 0.08% 0.08% 0.00% 0.00% 0.00% 0.00% 0.82% 1.18% 1.89%
60.09% 61.03% 60.26% 59.85% 59.85% 59.94% 59.47% 59.02% 58.50% 57.60% 56.99% 53.85%
No. of Shareholders 10,54116,25116,75616,46816,31615,41513,79813,13612,41610,51310,0889,753

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • May 2024
    Transcript
    Notes
    PPT
  • Feb 2024
    Transcript
    Notes
    PPT
  • Nov 2023
    Transcript
    Notes
    PPT
  • Aug 2023
    Transcript
    Notes
    PPT
  • May 2023
    Transcript
    Notes
    PPT
  • Feb 2023
    Transcript
    Notes
    PPT
  • Nov 2022
    Transcript
    Notes
    PPT
  • Sep 2022
    Transcript
    Notes
    PPT
  • Aug 2022
    Transcript
    Notes
    PPT
  • May 2022
    Transcript
    Notes
    PPT
  • Feb 2022
    Transcript
    Notes
    PPT
  • Nov 2021
    Transcript
    Notes
    PPT
  • Sep 2021
    Transcript
    Notes
    PPT
  • Jul 2021
    Transcript
    Notes
    PPT
  • Jun 2021
    Transcript
    Notes
    PPT
  • Feb 2021
    Transcript
    Notes
    PPT
  • Feb 2021
    Transcript
    Notes
    PPT
  • Nov 2020
    Transcript
    Notes
    PPT
  • Sep 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT
  • Jun 2020
    Transcript
    Notes
    PPT
  • Feb 2020
    Transcript
    Notes
    PPT
  • Nov 2019
    Transcript
    Notes
    PPT
  • Jul 2019
    Transcript
    Notes
    PPT
  • May 2019
    Transcript
    Notes
    PPT
  • Jan 2019
    Transcript
    Notes
    PPT
  • Nov 2018
    Transcript
    Notes
    PPT
  • Aug 2018
    Transcript
    Notes
    PPT
  • May 2018
    Transcript
    Notes
    PPT
  • Feb 2018
    Transcript
    Notes
    PPT
  • Nov 2017
    Transcript
    Notes
    PPT
  • Jul 2017
    Transcript
    Notes
    PPT
  • Feb 2017
    Transcript
    Notes
    PPT